These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38880216)

  • 1. Dapagliflozin attenuates fat accumulation and insulin resistance in obese mice with polycystic ovary syndrome.
    Lin B; Guo X; Lu W; Niu R; Zeng X; Chen Z; Wu C; Liu C
    Eur J Pharmacol; 2024 Aug; 977():176742. PubMed ID: 38880216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak L; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2021-2033. PubMed ID: 29572114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model.
    Lee YK; Oh TJ; Lee JI; Choi BY; Cho HC; Jang HC; Choi SH
    Eur J Pharmacol; 2023 Oct; 957():175946. PubMed ID: 37541370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
    Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
    Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
    Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
    Swe MT; Thongnak L; Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Lungkaphin A
    Clin Sci (Lond); 2019 Dec; 133(23):2415-2430. PubMed ID: 31769484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of SGLT2 Inhibitors on Improving Glucolipid Metabolism and Reproductive Hormone Status in Overweight/Obese Women with PCOS: A Systematic Review and Meta-Analysis.
    Zhang L; Wang Z; Kong L; Liu H; Ma Z; Xu M; Yushanjiang S; Yuan D; Yu L
    Reprod Sci; 2024 May; 31(5):1190-1203. PubMed ID: 38057530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
    Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
    Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
    Tanday N; Irwin N; Flatt PR; Moffett RC
    Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak LO; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Diabetes Obes Metab; 2018 Nov; 20(11):2617-2626. PubMed ID: 29923295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
    Zhang J; Xing C; Cheng X; He B
    Front Endocrinol (Lausanne); 2022; 13():1003238. PubMed ID: 36147577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
    Elkind-Hirsch KE; Chappell N; Seidemann E; Storment J; Bellanger D
    J Clin Endocrinol Metab; 2021 Sep; 106(10):3019-3033. PubMed ID: 34097062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome.
    Pruett JE; Torres Fernandez ED; Everman SJ; Vinson RM; Davenport K; Logan MK; Ye SA; Romero DG; Yanes Cardozo LL
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice.
    Han T; Fan Y; Gao J; Fatima M; Zhang Y; Ding Y; Bai L; Wang C
    Adipocyte; 2021 Dec; 10(1):446-455. PubMed ID: 34550043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin promotes white adipose tissue browning though regulating angiogenesis in high fat induced obese mice.
    Xiang L; Liu M; Xiang G; Yue L; Zhang J; Xu X; Dong J
    BMC Pharmacol Toxicol; 2024 Mar; 25(1):26. PubMed ID: 38504370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-fat diet induces significant metabolic disorders in a mouse model of polycystic ovary syndrome.
    Lai H; Jia X; Yu Q; Zhang C; Qiao J; Guan Y; Kang J
    Biol Reprod; 2014 Nov; 91(5):127. PubMed ID: 25100714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
    Lim S; Lee SH; Min KW; Lee CB; Kim SY; Yoo HJ; Kim NH; Kim JH; Oh S; Won JC; Kwon HS; Kim MK; Park JH; Jeong IK; Kim S
    Diabetes Obes Metab; 2024 Jun; 26(6):2188-2198. PubMed ID: 38425186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.
    Joannides CN; Mangiafico SP; Waters MF; Lamont BJ; Andrikopoulos S
    Diabetes Obes Metab; 2017 Aug; 19(8):1135-1146. PubMed ID: 28244693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α.
    Zhao H; Wang D; Xing C; Lv B; Wang X; He B
    J Steroid Biochem Mol Biol; 2023 May; 229():106265. PubMed ID: 36737028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.